vs
Side-by-side financial comparison of Foxx Development Holdings Inc. (FOXX) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Foxx Development Holdings Inc. is the larger business by last-quarter revenue ($16.7M vs $12.6M, roughly 1.3× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -25.6%, a 276.3% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs -4.4%).
FOXX vs SPRO — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.7M | $12.6M |
| Net Profit | $-4.3M | $31.5M |
| Gross Margin | 13.3% | — |
| Operating Margin | -13.3% | — |
| Net Margin | -25.6% | 250.7% |
| Revenue YoY | -4.4% | 24080.8% |
| Net Profit YoY | -400.9% | 250.9% |
| EPS (diluted) | $-0.62 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.7M | $12.6M | ||
| Q3 25 | $20.2M | $0 | ||
| Q2 25 | $13.9M | $0 | ||
| Q1 25 | $11.4M | $12.0K | ||
| Q4 24 | $17.5M | $52.0K | ||
| Q3 24 | $23.1M | $65.0K | ||
| Q2 24 | — | $114.0K | ||
| Q1 24 | — | $140.0K |
| Q4 25 | $-4.3M | $31.5M | ||
| Q3 25 | $-2.9M | $-7.4M | ||
| Q2 25 | $-4.1M | $-1.7M | ||
| Q1 25 | $-4.1M | $-13.9M | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $-2.3M | $-17.1M | ||
| Q2 24 | — | $-17.9M | ||
| Q1 24 | — | $-12.7M |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.6% | — | ||
| Q2 25 | 10.9% | — | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | 12.5% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -13.3% | — | ||
| Q3 25 | -4.4% | — | ||
| Q2 25 | -15.0% | — | ||
| Q1 25 | -31.3% | -122758.3% | ||
| Q4 24 | -12.8% | — | ||
| Q3 24 | -7.8% | -28604.6% | ||
| Q2 24 | — | -16720.2% | ||
| Q1 24 | — | -9987.1% |
| Q4 25 | -25.6% | 250.7% | ||
| Q3 25 | -14.2% | — | ||
| Q2 25 | -29.4% | — | ||
| Q1 25 | -35.9% | -115550.0% | ||
| Q4 24 | 8.1% | — | ||
| Q3 24 | -9.8% | -26380.0% | ||
| Q2 24 | — | -15668.4% | ||
| Q1 24 | — | -9049.3% |
| Q4 25 | $-0.62 | $0.56 | ||
| Q3 25 | $-0.42 | $-0.13 | ||
| Q2 25 | $-0.44 | $-0.03 | ||
| Q1 25 | $-0.58 | $-0.25 | ||
| Q4 24 | $0.20 | — | ||
| Q3 24 | $-0.65 | $-0.32 | ||
| Q2 24 | — | $-0.33 | ||
| Q1 24 | — | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8M | $40.3M |
| Total DebtLower is stronger | $84.8K | — |
| Stockholders' EquityBook value | $-11.8M | $59.0M |
| Total Assets | $42.0M | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $40.3M | ||
| Q3 25 | $1.5M | $48.6M | ||
| Q2 25 | $1.9M | $31.2M | ||
| Q1 25 | $3.8M | $48.9M | ||
| Q4 24 | $3.9M | $52.9M | ||
| Q3 24 | $9.2M | $76.3M | ||
| Q2 24 | — | $63.5M | ||
| Q1 24 | — | $82.3M |
| Q4 25 | $84.8K | — | ||
| Q3 25 | $90.2K | — | ||
| Q2 25 | $97.2K | — | ||
| Q1 25 | $100.5K | — | ||
| Q4 24 | $105.5K | — | ||
| Q3 24 | $110.3K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-11.8M | $59.0M | ||
| Q3 25 | $-7.9M | $26.5M | ||
| Q2 25 | $-5.4M | $32.8M | ||
| Q1 25 | $-1.6M | $33.8M | ||
| Q4 24 | $2.2M | $46.1M | ||
| Q3 24 | $457.2K | $65.5M | ||
| Q2 24 | — | $80.5M | ||
| Q1 24 | — | $96.2M |
| Q4 25 | $42.0M | $68.9M | ||
| Q3 25 | $49.8M | $54.2M | ||
| Q2 25 | $26.0M | $62.1M | ||
| Q1 25 | $32.9M | $77.7M | ||
| Q4 24 | $31.9M | $110.5M | ||
| Q3 24 | $49.5M | $135.2M | ||
| Q2 24 | — | $149.9M | ||
| Q1 24 | — | $167.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $284.2K | $-8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $284.2K | $-8.4M | ||
| Q3 25 | $-376.8K | $17.4M | ||
| Q2 25 | $-1.9M | $-17.7M | ||
| Q1 25 | $-178.4K | $-4.0M | ||
| Q4 24 | $-4.2M | $-23.4M | ||
| Q3 24 | $-243.5K | $12.8M | ||
| Q2 24 | — | $-18.7M | ||
| Q1 24 | — | $5.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-4.3M | — | ||
| Q3 24 | $-278.5K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -24.4% | — | ||
| Q3 24 | -1.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -2.97× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
